About
Dr William Dougall leads the Translational Oncology Discovery Laboratory at QIMR Berghofer. He has authored more than 80 peer-reviewed publications (>12,000 citations) and holds seven patents.
Prior to his appointment at QIMR Berghofer, Dr Dougall worked in industry and led multiple oncology drug development programs through IND and Phase I testing, including world-wide registration of denosumab, an agent widely used in oncology. He was the first to clone the novel TNF ligand/TNF receptor pair RANKL/RANK and demonstrate an obligate role for this pathway in development of lymph nodes, mammary glands and osteoclasts.
More recently, he has provided new insights into RANKL biology relevant to cancer immunotherapy as well as characterised two other novel targets for cancer immunotherapy.
Dr Dougall has extensive experience with preclinical tumor immunology models, clinical biomarker development (including IHC and transcriptomics) and has contributed to the translational design of over 20 oncology clinical trials (PI-III).